Ablative Radiotherapy to Consolidate Maximal Systemic Response in Metastatic Prostate Cancer (ANCHOR-Prostate)
NCT ID: NCT05457699
Last Updated: 2025-03-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
80 participants
INTERVENTIONAL
2022-12-30
2030-07-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
5 Fractions of Pelvic SABR With Intra Prostatic SABR Boost:
NCT04245670
Improving Sexual Quality of Life - Randomized Trial of Two vs Five MRI Guided SABR Treatments for Prostate Cancer
NCT05600400
Stereotactic Ablative Radiation Therapy for Prostate Cancer
NCT05668351
Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer
NCT06325046
Proton-Based Stereotactic Ablative Body Radiotherapy for Prostate Cancer
NCT03159676
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SABR consolidation
SABR
SBAR to PSMA-PET visible disease at maximal systemic therapy response.
Control - no SABR consolidation
no RT
no SABR, continued systemic therapy per SOC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SABR
SBAR to PSMA-PET visible disease at maximal systemic therapy response.
no RT
no SABR, continued systemic therapy per SOC
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
3.1.2 Diagnosis of metastatic prostate cancer having achieved maximum PSA response to SOC systemic therapy defined as two consecutive stable PSA within 6 months of regimen start. Stable PSA is defined as non- progressing (\<25% rise from nadir, per PCWG3 guidelines).
3.1.3 ECOG 0-2 3.1.4 PSA \> 0.2 ng/mL 3.1.5 1-5 sites of PSMA-PET avid disease amenable to SABR.
Exclusion Criteria
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre hospitalier de l'Université de Montréal (CHUM)
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CRCHUM
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
22.115
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.